An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Nuvig Therapeutics Appoints Julie Smith Chief Executive Officer
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Nuvig Therapeutics, a biopharma company focused on autoimmune diseases, appointed Julie Anne Smith as CEO and Board member. With over 20 years in the life sciences sector, she has previously led biotech firms through drug development. Pamela Conley transitions to Chief Scientific Officer, having co-founded the company. Smith's leadership comes as Nuvig's lead program progresses towards IND-enabling activities. Nuvig aims to develop novel therapies to restore immune function without broad immunosuppression.
Positive
Appointment of Julie Anne Smith as CEO brings over 20 years of relevant industry experience.
Transition to IND-enabling activities for lead program indicates significant progress.
Strong investor support received, facilitating rapid advancement of technology.
Negative
Management change may cause concerns about continuity and experience gaps.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--
Nuvig Therapeutics, Inc., a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, today announced the appointment of Julie Anne Smith as Chief Executive Officer (CEO) and member of the Board of Directors. Ms. Smith has over 20 years of experience in the life science industry, with a focus on leading private and public biotech companies through development and commercialization of therapeutics for orphan diseases. Pamela Conley, Ph.D., cofounder and founding CEO of Nuvig Therapeutics, will serve as the Company’s Chief Scientific Officer.
“The board is very grateful to Pam for leading Nuvig from inception to this exciting inflection point, as the company enters IND-enabling activities for its lead program,” said Kenneth Harrison, Ph.D., Director of Nuvig Therapeutics and Partner at Novo Ventures. “We are excited by the dynamic leadership, vision, and experience Julie brings to the company and look forward to working closely with her to advance Nuvig’s therapies to patients.”
Nuvig’s lead program is a novel recombinant human antibody fragment engineered to induce immune modulatory mechanisms that restore immune homeostasis and control inflammation in autoimmune diseases. Nuvig is extending this technology to build a pipeline of differentiated protein therapeutics that can be used in the context of varied but well-defined inflammatory and autoimmune diseases.
“I’m delighted to join Nuvig at this pivotal time as the team has received strong investor support and rapidly advanced its novel technology to the IND-enabling stage,” said Ms. Smith. “I look forward to working with Pam and the team to propel our development candidates into the clinic with the goal of providing new therapeutic options for autoimmune diseases without broad immunosuppression.”
Prior to Nuvig, Ms. Smith served as President and CEO of ESCAPE Bio, a biotech company developing precisely targeted therapies for genetic forms of neurodegeneration. She previously served as President and CEO of Raptor Pharmaceuticals, which developed and commercialized therapies for the orphan disease nephropathic cystinosis and chronic pulmonary infections before its acquisition by Horizon Pharmaceuticals. Ms. Smith also served as Chief Commercial Officer of Enobia Pharmaceuticals until it was acquired by Alexion Pharmaceuticals. Earlier in her career, she held roles at Jazz Pharmaceuticals, Genzyme, Novazyme, and Bristol-Myers Squibb. Ms. Smith serves as a director on the Boards of Exelixis (Nasdaq: EXEL) and Stoke Therapeutics (Nasdaq: STOK). Ms. Smith obtained her B.S. in biology from Cornell University.
About Nuvig Therapeutics
Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases. For more info, visit www.nuvigtherapeutics.com.
The new CEO of Nuvig Therapeutics is Julie Anne Smith, who has over 20 years of experience in the biotech industry.
What is the background of Julie Anne Smith?
Julie Anne Smith has previously served as CEO of ESCAPE Bio and Raptor Pharmaceuticals, focusing on developing therapies for orphan diseases.
What is the significance of the lead program at Nuvig Therapeutics?
Nuvig's lead program aims to develop a recombinant human antibody fragment to help manage autoimmune diseases by restoring immune balance.
Who is replacing Pamela Conley at Nuvig Therapeutics?
Pamela Conley is transitioning to the role of Chief Scientific Officer after her tenure as the founding CEO of Nuvig Therapeutics.
What are Nuvig Therapeutics' goals under the new leadership?
Under Julie Anne Smith's leadership, Nuvig aims to advance its therapies into clinical development, focusing on innovative treatments for autoimmune diseases.
